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doi:10.101Galactomannan Testing in Bronchoalveolar Lavage
Fluid Facilitates the Diagnosis of Invasive Pulmonary
Aspergillosis in Patients with Hematologic
Malignancies and Stem Cell Transplant Recipients
M. Hong Nguyen,1 Helen Leather,2 Cornelius J. Clancy,1 Christina Cline,2
Michael A. Jantz,2 Varsha Kulkarni,2 L. Joseph Wheat,3 John R. Wingard2Invasive pulmonary aspergillosis (IPA) is a major cause of mortality in patients with stem cell transplants and
hematologic malignancies. Timely diagnosis of IPA improves survival but is difficult to make.We evaluated the
effectiveness of bronchoalveolar lavage (BAL) galactomannan (GM) in diagnosing IPA in these populations by
retrospectively reviewing records of 67 consecutive patients, in whom 89 BAL GM tests were performed.
For patients with IPA, only the first BAL sample linked to the IPA episode was analyzed. Eighty samples
were associated with proven, 12 with probable, and 32 with possible invasive fungal infections (IFI), and
37 were associated with no IFI. Among patients with IFIs, 4 had proven, 11 probable, and 32 possible IPA.
Using BAL GM$0.5 (cutoff for serum GM) and$0.85 (optimal cutoff identified by receiver-operating char-
acteristic curve), the sensitivity in diagnosing proven or probable IPA was 73% (11/15) and 67% (10/15), re-
spectively, and specificity was 89% (33/37) and 95% (35/37). At these cutoffs, positive and negative predictive
values were 73% (11/15) and 83% (10/12), and 89% (33/37) and 87% (35/40), respectively. BAL GMwas more
sensitive than cytology (0%, 0/14), BAL culture (27%, 4/15), transbronchial biopsy (40%, 2/5), or serum GM
(67%, 10/15) for diagnosing IPA. BAL GM was$0.85 and $0.5 in 86% (6/7) and 100% (7/7) of patients with
proven or probable IPA who received a mold-active agent for #3 days. BAL GM added sensitivity to serum
GM and other means of diagnosing IPA, and was not impacted by short courses of mold-active agents.
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Invasive pulmonary aspergillosis (IPA) and other
types of invasive fungal infections (IFI) are major
causes of mortality and morbidity among hematopoi-
etic stem cell transplant (HSCT) recipients, patients
with hematologic malignancies, and solid-organ trans-
plant recipients. The incidence of IPA is approxi-
mately 15% to 20% among HSCT recipients and
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6/j.bbmt.2010.11.013[1-4], and case fatality rates are as high as 50% to
90% despite antifungal therapy [1,3-6]. Timely
diagnosis of IPA improves survival [7,8], but it is
difficult to make because of the limitations of current
diagnostic tests. Cultures and bronchoscopy-based
techniques such as cytology and histopathology of
tissue biopsies, for example, are limited by poor
sensitivity and specificity, and complications of inva-
sive procedures [9-11]. More recently, detection of
galactomannan (GM), a cell wall polysaccharide of
most Aspergillus and Penicillium species that is
released into the serum during growth in tissue, has
emerged as a useful adjunct to traditional diagnostic
tests [12]. Considered along with other tests and radio-
graphic and clinical findings, serum GM clearly im-
proves the ability to diagnose IPA [13]. Nevertheless,
the sensitivity of the test among HSCT recipients
and patients with hematologic malignancies is only
moderate, in the range of 61% to 71% by recent
meta-analysis [14]. Moreover, the positive predictive
value (PPV) of serum GM is limited by the relative in-
frequency of IPA, even among high-risk populations.1043
1044 Biol Blood Marrow Transplant 17:1043-1050, 2011M. H. Nguyen et al.Several studies have suggested that the sensitivity
of GM detection in diagnosing IPA can be improved
by applying the test to bronchoalveolar lavage (BAL)
fluid collected during bronchoscopy. Among HSCT
recipients and patients with hematologic malignancies,
detection of BALGM added to the diagnostic utility of
serum GM [15-22] and sensitivity and specificity
ranged from 58% to 100% and 94% to 100%,
respectively [16,18,23,24]. Despite these observations,
the role of BAL GM testing remains to be defined,
and at least 1 study reported high rates of false-
positive results [25].
We previously reported our experience with BAL
GM in diagnosing IPA among solid-organ transplant
recipients and nonimmunosuppressed hosts [26,27].
In this study, we review our experience with BAL
GM testing among patients admitted to the
hematologic malignancy or HSCT inpatient services
at the Shands Hospital at the University of Florida, as
the test was used by clinicians caring for these
patients. Our objective was to determine the
performance of BAL GM in diagnosing IPA.METHODS
Patients with acute leukemia receiving chemother-
apy or undergoing HSCT were eligible for this study,
which was approved by, and performed according to
the guidelines of the institutional review board at the
University of Florida. All patients received fluconazole
prophylaxis and had serum GM performed twice
weekly. Neutropenic fever was treated with cefepime,
and antibiotics were changed depending on culture re-
sults. Patients with persistent neutropenic fever de-
spite antibiotics underwent CT scans of the chest
and sinuses if sinopulmonary signs or symptoms oc-
curred. Those with new radiologic abnormalities, pos-
itive serum GM, or sinopulmonary signs or symptoms
suggestive of IFI were presumptively treated with vor-
iconazole while additional diagnostic assessment took
place. The routine voriconazole dose used at our cen-
ter was 6 mg/kg per os every 12 hours for 2 doses, fol-
lowed by 4 mg/kg per os twice a day. Bronchoscopy
was performed if pulmonary abnormalities were de-
tected radiologically. If zygomycosis was suspected
or there was a clinical reason that voriconazole was
contraindicated, amphotericin B lipid complex at
5 mg/kg intravenously was substituted.
Between September 2004 and December 2006,
BAL fluid collected for diagnostic purposes underwent
GM testing. GM testing was performed on all BAL
specimens at MiraVista Diagnostics (Indianapolis,
IN) using the PlateliaAspergillus enzyme immunoassay
(Bio-Rad Laboratories, Redmond, WA), as described
elsewhere [26,27]. The BAL GM results were made
available to the patients’ physicians, who made alldecisions regarding management. Although the
interpretive cutoff values for positive BAL GM have
not been established, we adopted the 0.5 cutoff
proposed for serum testing. Among patients with
IPA, only the first BAL sample associated with the
IPA episode was included in the evaluation.DEFINITIONS
IFI was classified into proven, probable, and possi-
ble using the European Organization for Research and
Treatment of Cancer-Mycoses Study Group [28]. IFI
was further subcategorized as proven or probable IPA
if the disease involved the lungs plus either culture
grew Aspergillus spp. or serum GM index was $0.5.
Detection of GM in BAL fluid was not included in
the classification of IPA in this study. Classifications
were made by 5 investigators who were blinded to
BAL GM results at the time (M.H.N., H.L., C.J.C.,
L.J.W., and J.R.W.). In the event of disagreements,
consensus was reached among the investigators.
Data Analysis
The sensitivity, specificity, PPV, negative predic-
tive value (NPV), and likelihood ratio for BAL GM
testing were calculated on a per-patient basis. The op-
timal cutoff for BAL GM was determined by receiver-
operating characteristic (ROC) analysis. Univariate
analysis of contingency data was done by chi-square
or Fisher’s exact test. Continuous variables were com-
pared using Mann-Whitney test. P values #.05 were
considered to be significant.RESULTS
BAL Samples and GM Indices
A total of 107 BAL samples from 67 unique pa-
tients were submitted for determination of GM index.
Eighty-nine samples from the 67 patients were sent for
diagnostic purposes, and 18 samples from 12 patients
were sent as follow-up during treatment for IFI includ-
ing IPA. Among the 89 diagnostic samples, 52 were as-
sociated with proven (n 5 8), probable (n 5 12) or
possible (n 5 32) IFI, and 37 were not associated
with IFI. The distribution of GM indices according
to IFI classification is presented in Figure 1.
Patient Demographics and Clinical Data
The median age of patients was 63 years, and 73%
(49/67) were men. Fifty-five percent (37/67) of pa-
tients received chemotherapy for hematologic malig-
nancies (acute myelogenous leukemia (AML) 5 16,
acute lymphocytic leukemia (ALL) 5 8, multiple my-
eloma 5 3, others 5 10), and 45% (30/67) underwent
HSCT (allogeneic 5 29, autologous 5 1). Thirty
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Figure 1. Distribution of BAL GM according to IFI.
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48% (32/67) had possible IFI, and 23% (15/67) did not
have an IFI. Among the patients with proven or prob-
able IFI, 75% (15/20) had IPA and 25% (5/20) had dis-
eases caused by other molds or associated with
negative cultures. Among the 5 patients with proven
or probable IFI but no evidence of IPA, 2 had proven
diseases because of Paecilomyces and Rhizopus (1 each).
The other 3 patients had lung biopsy–proven mold in-
fections, but cultures failed to yield an organism.
Two patients with proven IPA were infected with
A. fumigatus, and 1 with both A. fumigatus and A. niger.
The fourth patient with proven IPA did not have a pos-
itive respiratory culture prior to death; the lung culture
at autopsy grew A. flavus. Two cases of proven IPA
were diagnosed by histopathology and culture of trans-
bronchial biopsies (Table 1). The other 2 cases were
proven at autopsy (Table 1). Antemortem, 1 of these
cases was classified as probable IPA and the second
as possible IFI. Fifty percent (2/4) of patients with
proven IPA died. Among the 11 cases of probable
IPA, 9 were diagnosed by criteria that included posi-
tive serum GM indices (Table 1). In the remaining 2
cases, serum GM indices were negative, but patients
fulfilled other MSG/EORTC criteria for probable
IPA, including positive BAL cultures for Aspergillus
(Table 1). Fifty percent (6/12) of patients with proba-
ble IPA died.Performance of BAL GM Index
The BAL GM indices among patients with
proven/probable IPA (median: 2.91) were significantly
higher than among patients with possible IFI (median:
0.30, P 5 .006), IFI because of other molds (median:
0.18, P 5 .005) or no IFI (median: 0.2, P\ .0001).In addition, 73% (11/15) of BAL samples from pa-
tients with proven/probable IPA, 34% (11/32) from
patients with possible IFI, and 11% (4/37) from pa-
tients with no IPA had BAL GM indices $0.5 (P\
.001). The corresponding values for BAL GM index
.1.0 were 53% (8/15), 22% (7/32), and 6% (2/37), re-
spectively (P 5 .0005). Of note, none of the 4 false-
positive BAL GM tests at cutoff $0.5 (ie, indices of
0.53, 0.79, 1.34, and 5.28 in samples from patients
with no IPA) were associated with receipt of
piperacillin-tazobactam. The sensitivities and specific-
ities of BAL GM index for diagnosing IPA at various
cutoff values are presented in Table 2, along with
PPV and NPV values, and likelihood ratios. For this
study, BAL GM was not included in the definition of
IPA. If BAL GM was included in the definition of
IPA, however, 1 of 3 patients with tissue biopsy–
proven IFI but with negative culture, and 34% (11/
32) of patients with possible IFI would have been clas-
sified as a probable IPA (Figure 1).
Among the 11 patients with possible IPA and BAL
GM $0.5, all were treated with antimold antifungal
therapy for presumed pulmonary aspergillosis. None
underwent additional testing to confirm or rule out
the IPA diagnosis. Twenty-two patients with BAL
GM \0.5 were originally diagnosed with possible
IPA. One of these patients was found to have proven
IPA on postmortem examination; this patient was clas-
sified as proven IPA in our analysis. Among the 21 re-
maining patients with possible IPA, 10 did not receive
antimold antifungal therapy, and 5 received empiric
antimold antifungals that was discontinued within 7
days because of negative BALGM results. The median
follow-up for these 15 patients was 7 months (range:
4-17 months), during which time none developed
IPA. The other 6 patients received an antimold
Table 1. Basis for Classification of Cases of Proven and Probable IPA
Diagnosis at the Time of BAL Cytology BAL Culture TBBX TBBX Culture Serum GM BAL GM
Mold-Active Antifungal
Therapy at Time of
BAL; Duration
Proven IPA
1. Proven IPA Negative A. fumigatus Invasive hyphal elements A. fumigatus 0.31 0.2 None
2. Proven IPA Negative A. fumigatus, A. niger Invasive hyphal elements Negative 2.88 2.91 None
3. Possible IPA* Negative Negative† Not done Not done 0.39 0.39 None
4. Probable IPA* Negative A. fumigatus Not done Not done 0.12 8.28 None
Probable IPA—Serum GM $0.5 and BAL GM $0.85
5. Probable IPA Negative Negative Not done Not done 0.91 0.98 Caspofungin; 1 day
6. Probable IPA Negative Negative Negative Negative 0.95 3.62 Voriconazole; 1 day
7. Proven IFI,‡ probable IPA Negative Negative Not done Not done 1.24 7.21 Voriconazole; 3 days
8. Probable IPA Negative Negative Not done Not done 1.31 9.15 Voriconazole; 2 days
9. Probable IPA Negative Negative Not done Not done 1.52 3.39 None
10. Probable IPA Negative Negative Negative Negative 2.3 6.64 Voriconazole; 3 days
11. Probable IPA Negative Negative Not done Not done 2.98 8.06 None
Probable IPA—Serum GM $0.5 and BAL GM #0.85
12. Probable IPA Negative Negative Not done Not done 1.38 0.44 None
13. Probable IPA Not done Negative Not done Not done 10.75 0.64 Amphotericin B; 2 days
Probable IPA—Serum GM #0.5 and BAL GM $0.85
14. Probable IPA Negative A. fumigatus Negative Negative 0.29 0.85 Voriconazole; 1 day
Probable IPA—Serum GM #0.5 and BAL GM #0.5
15. Probable IPA Negative Aspergillus sp Not done Not done 0.10 0.1 Voriconazole; months
BAL indicates bronchoalveolar lavage; GM, galactomannan; IPA, invasive pulmonary aspergillosis; TBBX, transbronchial biopsy.
*Diagnosis of proven IPA was made at autopsy.
†Lung culture at autopsy grew A. flavus.
‡Diagnosis of proven IFI was made at autopsy.
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Biol Blood Marrow Transplant 17:1043-1050, 2011 1047BAL GM and Pulmonary Aspergillosisantifungal for $7 days. Three of these patients died
within 1month from their underlying hematologic dis-
order, but did not receive postmortem examinations.
As identified by the ROC curve, the optimal BAL
GM index for diagnosing proven and probable IPA
was$0.85, which resulted in sensitivity and specificity
of 67% (10/15) and 95% (35/37), respectively (Table
2). At this cutoff, 33% (5/15) of patients with
proven/probable IPA had false-negative BAL GM in-
dices. Two of these patients had proven IPA, 2 had
probable IPA based upon positive serum GM indices,
and 1 had probable IPA because of positive culture and
radiologic criteria. The BAL GM index was 0.69 in 1
patient and\0.5 in the other 4 patients.
Correlation Between BAL and Serum GM
For 70 BAL GM samples, a concomitant serum
GM test was performed within 3 days. There was no
correlation between the BAL and serum GM values
(Spearman r 5 .4) (data not shown).
Among the 23 paired samples from patients with
no IFI, 100% exhibited both negative BAL and serum
GM indices at cutoffs $0.85 and $0.5, respectively.
Among the patients with proven/probable IPA, BAL
and serum GM were in agreement for 73% (11/15)
of paired samples. BAL and serum GM indices were
both positive (BAL GM $0.85, and serum GM
$0.50) in 8 patients, and both negative in 3 patients.
Two patients had positive BAL GM but negative se-
rum GM, whereas 2 patients had negative BAL GM
and positive serum GM. As such, BAL GM testing
identified 2 patients not identified by serumGM index.
Incorporating either a positive BAL or serum GM in-
dex into the definition of IPA, therefore, would have
identified 80% (12/15) of patients with proven/proba-
ble IPA compared to 67% (10/15) identified using
serum GM alone. Among the remaining 30 patients
(5 with IFI because of molds other than Aspergillus
spp., and 25 with possible IFI), BAL and serum GM
indices were both negative in 70% (21/30) of patients;
the other 9 patients had positive BALGMand negative
serum GM indices.
BAL GM and Prior Mold-Active Antifungal
Agent Administration
The impact of mold-active antifungal therapy on
the performance of BAL GM was assessed using 80
samples recovered from patients with proven, proba-
ble, and possible IPA or no IFI, for whom a prior
history of antifungal use was available (Table 3).
Fifty-three percent (8/15), 20% (6/30), and 34% (12/
35) of BAL samples associated with proven or probable
IPA, possible IPA, and no IFI were obtained from pa-
tients receiving a mold-active antifungal agent at the
time of bronchoscopy. Among those with proven or
probable IPA, 3 patients received 1 dose (voriconazole,
Table 3. Impact of Mold-Active Antifungal Therapy on the Performance of BAL GM
No Prior Mold-Active Therapy Mold-Active Therapy Antifungal Usage Unknown
Proven and probable IPA (n 5 15) 7 8 0
% with BAL $0.5 57% (4/7) 88% (7/8)
% with BAL $0.85 57% (4/7) 75% (6/8)
Median BAL GM index 2.9 2.3
Proven IFI but no positive culture 3 0 0
IFI because of other molds 2 0 0
Possible IFI 24 6* 2
% with BAL $0.5 33% (8/24) 50% (3/6)
Median BAL GM index 0.30 0.30
No IFI 23 12† 2
BAL indicates bronchoalveolar lavage; GM, galactomannan; IPA, invasive pulmonary aspergillosis.
*Mold-active antifungal usage among the 6 patients with possible IFI: voriconazole (n 5 5, median duration: 3 doses, range: 2 doses- many months),
caspofungin, and amphotericin B (1 patient each, 1 dose).
†Antifungal usage among the 12 patients with no IFI included: voriconazole (n 5 8, median duration: 8 doses, range: 2 doses to many months), caspo-
fungin (n 5 2, 3, and 4 doses, respectively), combined voriconazole and caspofungin (n 5 1, 19 doses), and unknown (n 5 2).
1048 Biol Blood Marrow Transplant 17:1043-1050, 2011M. H. Nguyen et al.n5 2; caspofungin, n5 1), 2 patients received 2 doses
(voriconazole, n 5 1; amphotericin B product, n 5 1),
2 patients received 3 doses of voriconazole, and 1 pa-
tient received voriconazole for many months. All ex-
cept the last patient had BAL GM index $0.5 (range:
0.69-9.15). Eighty-eight percent (7/8) and 77% (6/8)
of patients who received a prior mold-active antifungal
had BAL GM indices $0.5 and $0.85, respectively.
Among the patients who did not receive a prior
mold-active antifungal, 57% (4/7) and 75% (6/8) had
BAL GM indices $0.5 and $0.85, respectively (P 5
.28 and .61, respectively). The median GM indices in
the BAL of patients with proven or probable IPA
who received and did not receive prior mold-active an-
tifungal were 2.3 and 2.9, respectively (P 5 .88).
Five patients with proven or probable IPA had
a positive culture for A. fumigatus at the time that
BAL GM was performed. Forty-three percent (3/7)
of patients with proven or probable IPA who did not
receive a mold-active antifungal had positive BAL
culture compared to 25% (2/8) who received a mold
active antifungal (p 5 .67).DISCUSSION
In this study, we evaluated the effectiveness of BAL
GM in diagnosing IPA among HSCT recipients and
patients with hematologic malignancies. Using BAL
GM index cutoffs $0.5 and $1.0 for test positivity,
the sensitivity in diagnosing proven or probable IPA
were 73% (11/15) and 53% (8/15), respectively.
Corresponding specificities were 89% (33/37) and
95% (35/37). Our results are in keeping with previous
studies of BAL GM in these patient populations, in
which sensitivity for the diagnosis of IPA ranged from
58% to 100% and specificity from 94% to 100%
[16,18,23,24]. We cannot conclusively define an
interpretive BAL GM breakpoint for diagnosing IPA
because of the small sample size. Nevertheless, our
ROC analysis suggested an optimal cutoff $0.85,which yielded sensitivity of 67% (10/15) and
specificity of 95% (33/37). The PPV and NPV values
at this cutoff were 83% (10/12) and 87% (35/40),
respectively. Taken together, our data suggest that
BAL GM testing has diagnostic value if used
judiciously in populations such as ours with a
significant prevalence of IPA.
Indeed, the key to interpreting our data is recog-
nizing that BAL GM was used as a diagnostic test in
patients at particularly high risk for IPA. As recently
discussed, BAL GM testing in this setting is used to
support a diagnosis of IPA [24,29]. As such, the
objective of testing is to optimize the PPV and
minimize false-positive results, which is generally
achieved as cutoff BAL GM values increase. Serum
GM, on the other hand, is typically used in the
HSCT and hematologic malignancy populations as
a screening test to exclude the diagnosis of IPA, in
which case a lower cutoff value achieves the objective
of maximizing NPV and minimizing false negative
results. In this regard, it is not surprising that BAL
GM indices $0.85 and $1.0 in our study were
superior in diagnosing IPA to cutoff $0.5, the value
widely used for serum GM testing. Our observation
is in keeping with the recommendation that BAL
GM $1.0 is optimal in patients with hematologic
diseases [24,29]. The impact of pretest likelihood on
the performance of BAL GM as a diagnostic test is
highlighted by earlier studies of solid organ
transplant recipients and nonimmunosuppressed
patients at our center, in whom disease prevalence
was much lower and PPV was 42% and 43%,
respectively [26,27].
Our findings support earlier reports that BAL GM
is better than traditional diagnostic procedures that
test BAL samples or lung tissue [9-11,16,24]. Indeed,
it is recognized that culture and cytology of BAL
samples are frequently negative despite extensive
fungal infection observed in tissue histopathology
[11]. The sensitivity of BAL culture among our
patients with proven or probable IPA was only 33%
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gal elements in any of the samples (sensitivity of 0%, 0/
15). The sensitivity of transbronchial biopsy of 40%
(2/5) was better, but the fact that biopsies were per-
formed in only 5 patients highlights the reluctance to
subject these high-risk patients to invasive procedures.
It should be pointed out that if the BAL GM was in-
cluded in the definition of IPA, 1 of 3 patients with tis-
sue biopsy-proven IFI but with negative culture, and
34% (11/32) of patients with possible IFI would have
been classified as a probable IPA (Figure 1). In the ab-
sence of positive cultures or histopathology, we cannot
exclude the possibility that the BAL GM in the 11 pa-
tients with possible IFI may be a false-positive, despite
clinical findings consistent with an invasive fungal in-
fection. The possibility of false-positive results high-
lights the need for judicious use of BAL GM testing
in settings where the suspicion for IPA is high. False-
positive GM has been associated with the carryover
of small amounts of GM during the production of
fermentation products in Penicillium, such as in the
case of antibiotics [30], or in A. niger, such as in the
case of Plasmalyte [31]. A false-positive test can also
occur because of contamination of the specimen at col-
lection, processing, transport, or testing.
It is particularly notable that the performance of
BALGMwas not impacted by short courses of antifun-
gal agents. Indeed, BAL GM indices were $0.85 and
$0.5 in 86% (6/7) and 100% (7/7) of patients, respec-
tively, with proven or probable IPA who received
a mold-active agent for #3 days at the time of bron-
choscopy. Previous studies have shown that antimold
therapy decreases the sensitivity of GM testing by re-
ducing fungal burdens [11,15,23,32-35]. Based on
a relatively small sample size, we found that there
was no significant difference in the sensitivity of
positive BAL GM among patients with proven or
probable IPA who received #3 days of an antimold
agent prior to bronchoscopy compared to those who
did not. Experimental evidence indicates that
antimold therapy might have a greater impact on GM
detection in the serum than alveolar fluid, consistent
with the levels and time course of drug penetration at
the respective sites [36].
For patients with proven or probable IPA, the
agreement between BAL and serum GM test results
was 73% (11/15). We identified 2 patients who had
positive BAL GM indices but negative serum indices,
and 2 patients with positive serum GM indices but
negative BAL indices. In part, such discordance might
reflect the fact that the airway and vascular compart-
ments are involved in different stages of disease. Using
in vitro and rabbit models of IPA, investigators dem-
onstrated that the appearance of GM in the alveolar
fluid correlates with the airway cellular invasion of
Aspergillus [36]. Serum GM, on the other hand, corre-
lates with the subsequent penetration of hyphaethrough the endothelial cell layer [12,36]. The
experimental models and our data, therefore, suggest
that BAL and serum GM testing are complementary.
Although the interpretation of our data is
complicated by the fact that serum GM is part of the
current definition for probable IPA, we found that
the presence of either a positive BAL or serum GM
resulted in diagnostic sensitivity of 80% (12/15),
superior to either test alone. At the same time, we
clearly demonstrated that negative BAL and serum
GM indices did not exclude IPA. In 3 patients with
proven or probable IPA, both BAL and serum GM
indices were negative. One of these patients had
biopsy-proven IPA, which cultures were positive for
A. fumigatus. The second patient underwent BAL
a month apart, neither of which yielded a diagnosis
for worsening infiltrates seen on chest CT scan. Ulti-
mately, an autopsy showed aspergillosis of the lungs
and brain. The third patient with negative BAL and se-
rum indices had probable IPAbased on a chestCT sug-
gestive of a fungal infection and BAL culture that grew
A. fumigatus.
It is important to acknowledge that the availability
of BAL GM results to providers may have impacted
subsequent diagnostic evaluations. We could not find
conclusive evidence for this upon individual case re-
views, but it is possible that such practices introduced
unrecognized biases in interpreting test performance.
Nevertheless, our data demonstrate that BAL GM
adds sensitivity to serumGM and other bronchoscopic
means for diagnosing IPA. Although our results are
encouraging, it should be acknowledged that up to
25% of patients in our study with IFI were infected
with fungi other than Aspergillus. The increasing use
of voriconazole and echinocandin agents might con-
tribute to the emergence of non-Aspergillus molds,
and the utility of BAL GM testing for these cases is
less well established. Therefore, continued efforts are
needed to develop novel tests for the diagnosis of IFI.ACKNOWLEDGMENTS
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